Get the Daily Brief
Latest Biotech News
Roche's oral SERD clears planned interim: adjuvant breast cancer hit
Roche reported a planned interim success in a Phase III adjuvant trial of its oral selective estrogen receptor degrader, giredestrant, showing the agent reduced early recurrence when given after...
NIH grant cuts halt 383 trials — 74,311 participants left in limbo
A Harvard‑led analysis published in JAMA Internal Medicine found NIH funding cuts from late February to mid‑August led to termination of 383 trials, affecting more than 74,000 enrolled...
Iambic raises $100M to move AI‑discovered oncology candidates toward clinic
Iambic secured $100 million to advance AI‑discovered oncology drugs into clinical testing, following presentation of data for a breast cancer candidate at a recent oncology conference. The...
Solve Therapeutics pulls in $120M: targets best‑in‑class ADCs
Solve Therapeutics closed a $120 million financing round to develop next‑generation antibody‑drug conjugates, including novel linker technologies the company says can improve therapeutic index and...
Rapid sepsis test matches blood culture: Ocean Dx hits 100% sensitivity & specificity
Ocean Dx reported a clinical evaluation in which its rapid sepsis assay matched the gold‑standard reference, returning 100% sensitivity and 100% specificity against blood cultures while...
Foli‑seq captures the 'exfoliome': noninvasive fecal RNA tool maps gut immune states
Researchers introduced exfoliome sequencing (Foli‑seq) — a targeted, multiplexed amplicon approach that profiles host mRNA from exfoliated gut cells in feces — and demonstrated the method can...
Neural stem cell transplant restores primate forelimb function — major translational step
A Nature Biotechnology study reported that transplanting human embryonic stem cell‑derived spinal cord neural stem cells (H9‑scNSCs) into injured rhesus monkeys restored forelimb and hand function...
J&J buys Halda for $3.05B: acquires RIPTAC platform and lead prostate drug
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash, securing Halda’s regulated induced proximity targeting chimera (RIPTAC) platform and lead candidate HLD-0915....
Ziihera Phase 3: zanidatamab shows PFS and OS gains in first-line GEA
Zymeworks and partners Jazz Pharmaceuticals and BeOne announced positive topline results from the Phase 3 HERIZON‑GEA‑01 trial testing zanidatamab (Ziihera) with chemotherapy, with and without...
Stem cell transplant restores primate hand function: path to clinical translation
Two Nature Biotechnology reports revealed that transplanting human embryonic stem cell‑derived spinal cord neural stem cells restored forelimb/hand function in nonhuman primates with cervical...
Foli‑seq: fecal exfoliome sequencing maps gut immune and epithelial states
Researchers at Columbia University unveiled exfoliome sequencing (Foli‑seq), a targeted amplicon approach that profiles host mRNA from exfoliated gut cells in feces to monitor intestinal and...
Roche previews Axelios 1: fast SBX sequencing shows cancer‑genomics promise
Roche and early users presented early data for the Axelios 1 sequencing‑by‑expansion (SBX) nanopore platform at AMP, positioning the instrument for rapid cancer genomics and ctDNA analysis....
Thermo Fisher pushes next‑day comprehensive genomic profiling on Genexus
Thermo Fisher presented multicenter data showing its Oncomine Comprehensive Assay Plus running on the automated Ion Torrent Genexus platform can deliver comprehensive genomic profiling (CGP) with...
Ocean Dx sepsis test matches gold standard: 5‑hour, direct whole‑blood assay
A clinical evaluation showed Ocean Dx’s rapid sepsis assay detected more than 1,000 bacterial species directly from whole blood with 100% sensitivity and 100% specificity versus reference blood...
Artios raises $115M: DNA damage‑response specialist funds clinic expansion
Artios Pharma closed an oversubscribed $115 million Series D to advance its DNA damage response (DDR) pipeline after delivering encouraging Phase I/IIa readouts for its lead programs. The...
Sofinnova closes €650M flagship fund: more dry powder for early biotech
Sofinnova Partners raised €650 million (~$750 million) for its Capital XI flagship fund, exceeding targets and earmarking capital for early‑stage therapeutics and medtech investments. Partners...
Nuvalent’s ALK drug posts durable responses: clinical rival to Pfizer’s Lorbrena
Nuvalent disclosed Phase 1/2 data for neladalkib in ALK‑positive lung cancer patients who progressed on prior ALK inhibitors, reporting a 31% overall response rate with many responses durable at...
J&J snaps up Halda for $3.05B — new anti-resistance approach added
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash, bringing Halda’s regulated induced proximity targeting chimera (RIPTAC) platform and lead candidate HLD‑0915 into...
Zanidatamab wins phase 3 — potential new HER2 standard in gastroesophageal cancer
Zymeworks’ zanidatamab (Ziihera®) produced statistically significant and clinically meaningful improvements in progression‑free survival in the Phase 3 HERIZON‑GEA‑01 trial versus trastuzumab plus...
Primates regain hand function — neural stem cell graft restores forelimb control
Two Nature Biotechnology papers report that transplantation of human embryonic stem cell‑derived spinal neural stem cells produced extensive restoration of forelimb function in rhesus monkeys with...